Silencing of COL6A3 in GBM cells suggested a role for α3(VI) in DNA damage response pathways, which was validated via Western blotting, showing reduced yH2aX in α3(VI)-depleted cells. The gene discussed is COL6A3; the disease is glioblastoma.